{
    "root": "2ffe04ab-c215-a732-e063-6294a90ac37e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lithium Carbonate",
    "value": "20250310",
    "ingredients": [
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "LITHIUM CARBONATE",
            "code": "2BMD2GNA4V",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6504"
        }
    ],
    "indications": {
        "text": "lithium mood-stabilizing agent indicated monotherapy treatment bipolar disorder : \u2022 treatment acute manic mixed episodes patients 7 years older [ ( 14 ) ] \u2022 maintenance treatment patients 7 years older [ ( 14 ) ]",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting adults pediatric patients 30 kg ( 2.2 ) : \u2022 capsules : 300 mg , three times daily recommended starting pediatric patients 20 30 kg ( 2.2 ) : \u2022 capsules : 300 mg twice daily obtain serum lithium concentration assay 3 days , drawn 12 hours last oral dose regularly patient stabilized . acute manic mixed episodes ( patients 7 years older ) : titrate serum lithium concentrations 0.8 1.2 meq/l ( 2.2 ) . maintenance treatment bipolar disorder ( patients 7 years older ) : titrate serum lithium concentrations 0.8 1 meq/l ( 2.2 ) . pre-treatment screening : evaluate renal function , vital signs , electrolytes , thyroid function , concurrent medications , pregnancy status ( 2.1 ) . mild moderate renal impairment ( cler 30 89 ml/min ) : start dosages less patients normal renal function , titrate slowly frequent monitoring ( 2.5 ) . severe renal impairment ( cler < 30 ml/min ) : avoid lithium ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "lithium carbonate capsules , usp 600 mg supplied hard gelatin capsules , pink cap imprinted \u2018 g222 \u2019 light gray body imprinted \u2018 600 \u2019 , filled white off-white granules . ndc : 70518-2312-00 ndc : 70518-2312-01 packaging : 100 1 box packaging : 1 1 pouch storage dispense store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight , child-resistant container defined usp/nf . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "lithium contraindicated patients known hypersensitivity inactive ingredient lithium carbonate capsule [ ( 6 ) ] .",
    "indications_original": "Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder:\n                  \n                     \u2022\u00a0\u00a0Treatment of acute manic and mixed episodes in patients 7 years and older \n        \n  \n   [see Clinical Studies (\n         \n   \n    14)]\n        \n  \n   \n                     \n                     \u2022\u00a0\u00a0Maintenance treatment in patients 7 years and older \n        \n  \n   [see Clinical Studies (14)]",
    "contraindications_original": "Recommended starting dosage for adults and pediatric patients over 30 kg ( 2.2 ): \u2022\u00a0\u00a0Capsules: 300 mg, three times daily Recommended starting dosage for pediatric patients 20 to 30 kg ( 2.2 ): \u2022\u00a0\u00a0 Capsules: 300 mg twice daily Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Acute Manic or Mixed Episodes (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L ( 2.2 ). Maintenance Treatment for Bipolar I Disorder (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1 mEq/L ( 2.2 ). Pre-treatment Screening: Evaluate renal function, vital signs, electrolytes, thyroid function, concurrent medications, and pregnancy status ( 2.1 ). Mild to Moderate Renal Impairment (CLer 30 to 89 mL/min): Start with dosages less than those for patients with normal renal function, titrate slowly with frequent monitoring ( 2.5 ). Severe Renal Impairment (CLer < 30 mL/min): Avoid use of lithium ( 2.5 ).",
    "warningsAndPrecautions_original": "Lithium Carbonate Capsules, USP\n                  600 mg supplied as hard gelatin capsules, pink cap imprinted with \u2018G222\u2019 and light gray body imprinted with \u2018600\u2019, filled with white to off-white granules.\n                  NDC: 70518-2312-00\n                  NDC: 70518-2312-01\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Storage and Dispense\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, child-resistant container as defined in the USP/NF.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate capsule \n       \n \n  [see Adverse Reactions (\n        \n  \n   6)].",
    "drug": [
        {
            "name": "Lithium Carbonate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6504"
        }
    ]
}